Transcend Capital Advisors LLC Buys New Position in Regeneron Pharmaceuticals, Inc. $REGN

Transcend Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 679 shares of the biopharmaceutical company’s stock, valued at approximately $382,000.

Several other institutional investors and hedge funds have also modified their holdings of REGN. Dodge & Cox raised its holdings in Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares during the period. Norges Bank purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $628,151,000. Acadian Asset Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 234.7% in the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock worth $244,480,000 after buying an additional 326,583 shares during the period. Loomis Sayles & Co. L P lifted its position in shares of Regeneron Pharmaceuticals by 18.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after buying an additional 305,089 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 26.5% during the 2nd quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock valued at $564,808,000 after acquiring an additional 225,078 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: JPMorgan raised its price target to $950 and kept an “overweight” rating — a sizable increase that signals strong analyst conviction and adds meaningful upside to the stock. Benzinga
• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and lifted its target to $865, reflecting continued confidence after Regeneron’s Q4 beat. Benzinga
• Positive Sentiment: Cantor Fitzgerald raised its target to $800 and maintained an “overweight” view, another vote of confidence supporting the rally. Benzinga
• Positive Sentiment: Wells Fargo lifted its price target to $800 (equal weight) — a modest boost that still reinforces momentum from the quarter. Benzinga
• Positive Sentiment: Regeneron highlighted new EYLEA HD presentations (QUASAR and ELARA results) at Angiogenesis 2026 — positive clinical data that can support the ophthalmology franchise outlook. EYLEA HD Presentations
• Positive Sentiment: Coverage roundup notes analysts revising forecasts after Regeneron’s upbeat Q4 results—consensus attention on the beat is lifting sentiment. Analyst Revisions After Q4
• Neutral Sentiment: Morgan Stanley nudged its target to $769 but kept an “equal weight” rating — a very small adjustment that signals limited near‑term upside from their view. TickerReport
• Neutral Sentiment: Market commentary pieces discuss Regeneron’s pipeline progress and valuation gap; useful context for longer‑term investors but not an immediate catalyst. Yahoo Finance
• Negative Sentiment: Truist trimmed its target slightly to $818 (still a “buy”) — a small downward tweak that may temper upside expectations from some investors. Benzinga

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of recent analyst reports. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research report on Monday. Canaccord Genuity Group increased their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Scotiabank boosted their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Finally, Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a research report on Monday. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $790.64.

Regeneron Pharmaceuticals Trading Up 0.6%

Shares of REGN stock opened at $759.18 on Wednesday. The company has a market cap of $79.79 billion, a PE ratio of 18.27, a price-to-earnings-growth ratio of 1.95 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The stock’s 50 day simple moving average is $757.70 and its two-hundred day simple moving average is $654.25. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.77 and a quick ratio of 4.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the company posted $12.07 EPS. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be paid a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.47%.

Insider Activity

In related news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.